Podcasts about Barrow Neurological Institute

In today's podcast, Dr. Kevin Yuen, a world-renowned neuroendocrinologist, frequent PWN contributor, and medical director of the Barrow Neurological Institute, discusses Crinetics' new acromegaly drug Paltusotine (Palsonify™). The drug was recently approved by the Food and Drug Administration. Dr. Yuen explains how this new medication works and provides an excellent clinical perspective on his views to evaluating new therapies. Read Dr. Kevin Yuen's PWN articles here.

  AZ Bio Week & Life Sciences Innovation w/ Joan Koerber-Walker - AZ TRT S06 EP19 (281) 10-12-2025   Things We Learned This Week AZ Bio mission to improve life and bioscience, & make AZ a Top Ten Bioscience state AZ Bio Week 2025 - Oct. - 5 Days Talks, Events & Awards AZ Advances - nonprofit donation to biotech startups Aqualung Therapeutics is treating inflammation in the lungs, get people off ventilators & save lives Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Anuncia Medical has a Re-Flow product to help drain fluid from the brain, treats Hydrocephalus     Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   LKIN: https://www.linkedin.com/in/joankoerberwalker  www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations. In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and  represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015),  in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more.         AZBio:  Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org  MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.   AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.   Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.   Notes:   Seg 1   Biotech and life sciences industry in Arizona, has 3000 businesses and 36,000 employees. The economic impact in 2021 was $38.5 billion. AZ Bio would like to double, so by 2033, the impact would be $78 billion.   Examples of biotech companies in Arizona are Medtronic that makes medical devices, WL Gore, material sciences. Other companies in diagnostics, there are Sonoran Quest which does testing. This also Castle Bio Sciences, deals in cancer treatment. Some medicine companies are Bristol, Myers, and Calvari who deals in cancer drugs. Calvari is the bio science company of the year in 2024.   AZ Bio Science Week started in 2017. AZ Bio week starts Oct. 13 (2025) and has events daily from Monday to Friday.     Example of one of the many companies involved with AZ Bio week:   CND Life Sciences - CND's Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.   NIH - National Institute of Health gives grants or funding to universities, hospitals and even companies for medical research.   Takes time to build a medical device type product, a few years to decades.   Government is an important partner, that provides financial support. Examples are Medicare research, workforce help, and tax breaks. Many organizations like this are publicly funded with government and university help.  $25 billion in funding over the last 20 years in Arizona in bio investment. Government funded $5 billion, that's from state and federal sales tax at a penny per. $112 million funding to universities in 2022. Combination of industry, government and philanthropy. Discovery phase - university helps develop the IP and research. Technology is spun out of the university to corporate development by companies. The AZ Board of Regents owns the patents. They license the patents to companies. Then you have regulatory.  Distribution of a product. Successful products are profitable. They have a royalty that pays to the company, the university and the government. Example of this was the University of Florida created Gatorade in the 1970s and still gets royalties today. Process takes 10 to 15 years, with hundreds of people involved. Clinical trials of any type of drug takes years.   Creation of the Covid vaccine was an outlier, as many people had Covid at the time so it was very easy to put together big study groups       Seg 2   Examples of newer companies in biotech field –   Neo clinical stage company dealing in heart health with aortic artery for the abdomen.   Another new company is prim dealing in MCT deficiency, compound growth and they are in clinical and testing stages.   Drugs get tested through computer models, and then on animals. Always have to worry about safety and ethics. FDA has very strict rules. You do not put people at risk, after monitor, during test and post monitoring. There's high-level quality control.       AZ Bio has members that are in the bioscience industry with current companies   AZ Advances is about bio startups in early stage companies It's a 501 C nonprofit charity that is funding, internships, and education   Patient is not only the client, but the purpose for why biotech companies exist     Neuralink Corp. is an American neurotechnology company that has developed as of 2024 implantable brain–computer interfaces. It was founded by Elon Musk and a team of eight scientists and engineers. Neuralink was launched in 2016 and first publicly reported in March 2017.   Neuralink's first human patient, Noland Arbaugh, is an Arizona native who received his implant in January 2024 at the Barrow Neurological Institute in Phoenix. He will appear at Arizona Bioscience Week 2025     https://www.azbio.org/azbw2025     Events Summary:   Monday - Women in Biotech Leading Women: Biotech & Beyond Join us for an evening of conversation and connections with our community's leading women as we kick off Arizona Bioscience Week in style!   Tuesday - Fundraising Fundraising Strategies for Life Science Startups  A compelling narrative is crucial when you are fundraising and communicating with life science investors.  This Life Science Nation (LSN) Global Fundraising Bootcamp covers topics related to executing a successful fundraise for your startup.      Wednesday – AZ Bio awards, philanthropy, entertainment, and AZ Advances The 21st Annual AZBio Awards & AZAdvances After Party Celebrate with the Educators, Researchers, and Organizations that are making life better for people in Arizona and around the world.  Join us at the Phoenix Convention Center as we honor the 2024 AZBio Award Winners. Hundreds of health innovators and business leaders will be celebrating at the 20th Annual AZBio Awards.   Thursday -  AZAdvances   AZ Advances Health Innovation Summit This exclusive event will bring together health innovation leaders to share how are moving Arizona forward as we make life better for the people we serve.   AZ Advances: Arizonans are advancing life changing and life saving innovations along the path from discovery to development to delivery. AZAdvances is developing the funding that will help advance health innovations in Arizona today and for generations to come.  Charitable donations to the AZAdvances fund at the Opportunity Through Entrepreneurship Foundation, an Arizona based 501c3 public charity, are a way to support the creation of tomorrow's medical innovations.    Friday - Voice of the Patient Patients are the reason we do what we do.  Join the conversation on life science innovation from the patient perspective.        Seg. 3 Best of AZ Bio clips:   AZ Bio & Life Sciences Innovation w/ Joan Koerber-Walker - BRT S04 EP10 (172) 3-5-2023   Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   Full Show: HERE     Guest: Stan Miele President & CBO Aqualung Therapeutics Corp LKIN: HERE www.aqualungtherapeutics.com   Stan Miele Bio: A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries. Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc.  He was also President of Sucampo Pharma Americas for 6 years.   He was instrumental on some key licensing agreements for Sucampo, inclusive of the agreement with Abbott Japan, and also Takeda Pharmaceuticals (now Shire).  He is actively part of the team ensuring proper execution of clinical development, manufacturing, licensing, capital funding, alliances, and ensuring Aqualung meets all critical milestones.  He will be helping the company move toward accelerating the pipeline/platform technology and moving eNamptor™ toward commercialization.   Aqualung Therapeutics  Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung's strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.   Full Show: HERE       Seg. 4 – Clips from:  Preventing Cancer with a Vaccine w/ Stephen Johnston of Calviri  - BRT S04 EP17 (179) 4-23-2023   Guest: Stephen Johnston Founding CEO, Calviri Inc.  LKIN: HERE https://calviri.com/   Bio: Chief Executive Officer & Chairman of the Board Stephen Albert Johnston is the inventor of the Calviri's central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute's Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.     Calviri Inc.  We are determined to offer humanity a better life, free from cancer. While our goal is hugely ambitious, we are intensely driven to rid the planet of worry from cancer. Calviri's mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine.   Full Show: HERE       ReFlow to Help Treat Hydrocephalus w/ Elsa Abruzzo & Mark Geiger of Anuncia Medical - BRT S04 EP23 (186) 6-11-2023     Guest: Elsa Chi Abruzzo RAC, FRAPS – President Elsa Chi Abruzzo is a medical device executive, entrepreneur, and a founding member of Anuncia, Inc., Alcyone Therapeutics, Arthromeda, Inc. and Cygnus Regulatory. Elsa has a 30+ year successful product development, operations, regulatory, quality, and clinical track record in med tech Industries. Her experience includes leadership positions at Baxter, Cordis JNJ, CryoLife, Percutaneous Valve Technologies, AtriCure, InnerPulse, Merlin MD, Sapheon, and PTS Diagnostics. Elsa earned a BS in engineering from the University of Miami in Coral Gables, FL and is regulatory affairs certified and a Regulatory Affairs Professional Society Fellow, recognized for her leadership in Regulatory and Quality by MDDI.   https://anunciamedical.com/the-anuncia-story/#team https://www.linkedin.com/in/elsachiabruzzo/   https://anunciamedical.com/ About Anuncia Conceptualized in 2014 in collaboration with Boston Children's Hospital and spun out of Alcyone Therapeutics in 2018, Anuncia's patented portfolio of technologies are intended to provide peace-of-mind through innovation. Our core ReFlow™ technology uses a simple finger depression of a soft silicone dome located under the patient's scalp to produce a noninvasive, one-way flush of the patient's own CSF directed toward the ReFlow™ catheter to restore or increase CSF flow through a non-flowing shunt and potentially avoid emergency surgery.  Learn More     The name Anuncia comes from Panthera Uncia, the species name of the snow leopard. These animals live in mountainous regions of Asia and have been called by the World Wildlife Foundation “Guardians of the Headwaters” as they roam the headwater areas of the western basins. The origin of the word hydrocephalus comes from the Greek hudrokephalon, from hudro ‘water'+ kephalē ‘head'. The snow leopard, or Guardian of the Headwaters, is a symbol of Anuncia's dedication to improve daily quality of life for the millions of underserved patients with hydrocephalus and other CSF disorders, as well as their families, who suffer from the clinical, economic, and emotional burden of repeat revision brain surgery due to VP shunt occlusions.      Full Show: HERE           Best of Biotech from AZ Bio & Life Sciences to Jellatech: HERE   Biotech Shows: HERE   AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023      ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What's Ahead," In this episode, Joyce Lee-Iannotti, MD, PhD, division chief of both the Stroke Center and the Comprehensive Sleep Center at Barrow Neurological Institute, discusses her presentation from the 2025 SLEEP Annual Meeting focused on the glymphatic system's role in stroke. She outlines the science behind this brain-cleansing pathway, its dependence on sleep quality, and how its dysfunction may worsen outcomes in both ischemic and hemorrhagic stroke. Lee-Iannotti also details practical, evidence-backed strategies for optimizing glymphatic clearance—from sleep posture and sleep apnea treatment to emerging pharmacologic options like orexin antagonists. In addition, she highlights major gaps in clinician awareness and offers calls to action for improving sleep assessments in stroke care. Looking for more Sleep disorders discussion? Check out the NeurologyLive® Sleep disorders clinical focus page. Episode Breakdown: 1:00 – Overview of the glymphatic system and its relevance in stroke care 2:55 – Evidence linking sleep quality and glymphatic activity in stroke prevention and recovery 7:40 – Neurology News Minute 10:05 – Potential interventions: pharmacologic and nonpharmacologic approaches to enhance glymphatic function 13:10 – Raising clinical awareness of sleep's role in stroke and neurologic disease management The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Grants Priority Review, Sets PDUFA Date for Hunter Syndrome Treatment Tividenofusp Alfa FDA Approves Updated Label for Alzheimer Therapy Donanemab to Lower ARIA-E Risk Exablate Neuro Gains FDA Approval for Staged Bilateral Focused Ultrasound in Advanced Parkinson Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Une étude publiée en mai 2025 dans la revue JAMA Network Open, menée par le Barrow Neurological Institute et la Mayo Clinic, a révélé une association significative entre la proximité des terrains de golf et un risque accru de développer la maladie de Parkinson.Méthodologie de l'étudeLes chercheurs ont analysé les données de 419 patients atteints de la maladie de Parkinson et de 5 113 témoins appariés, issus du Rochester Epidemiology Project, couvrant une période de 1991 à 2015. Ils ont examiné la distance entre le domicile des participants et les terrains de golf, ainsi que la nature de leur approvisionnement en eau potable.Résultats principauxLes personnes résidant à moins d'un mile (environ 1,6 km) d'un terrain de golf présentaient un risque accru de 126 % de développer la maladie de Parkinson par rapport à celles vivant à plus de six miles.Le risque diminuait progressivement avec l'éloignement du terrain de golf, suggérant une relation dose-réponse.Les individus vivant dans des zones desservies par des systèmes d'eau potable alimentés par des nappes phréatiques situées sous des terrains de golf avaient un risque presque doublé de développer la maladie, comparé à ceux vivant dans des zones sans terrain de golf.Hypothèses explicativesLes terrains de golf sont souvent entretenus avec des quantités importantes de pesticides pour maintenir la qualité des pelouses. Aux États-Unis, l'utilisation de pesticides sur les terrains de golf peut être jusqu'à 15 fois supérieure à celle observée en Europe. Ces substances chimiques peuvent s'infiltrer dans les nappes phréatiques, contaminant ainsi l'eau potable des zones avoisinantes.De plus, certaines zones géologiques, comme celles avec des sols perméables ou des formations karstiques, facilitent la migration des pesticides vers les sources d'eau souterraines.Limites de l'étudeBien que l'étude établisse une association entre la proximité des terrains de golf et un risque accru de maladie de Parkinson, elle ne prouve pas une relation de cause à effet. Les chercheurs n'ont pas mesuré directement les niveaux de pesticides dans l'eau potable ni pris en compte d'autres facteurs environnementaux ou génétiques pouvant influencer le risque.Cette étude souligne l'importance de considérer les facteurs environnementaux, tels que l'utilisation intensive de pesticides sur les terrains de golf, dans l'évaluation des risques de maladies neurodégénératives comme la maladie de Parkinson. Des recherches supplémentaires sont nécessaires pour confirmer ces résultats et élaborer des recommandations de santé publique appropriées. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

For this month's community spotlight, we speak with Dr. Daniel Gonzalez with Barrow Neurological Institute about Stroke Awareness Month.

Governor Katie Hobbs signed a bill Wednesday making it a state crime for protesters and others to set up encampments on college campuses. After a surgery at Barrow Neurological Institute in Phoenix, one man managed to get back to work in his patio studio. A federal judge in Phoenix heard arguments Wednesday from the nonprofit Apache Stronghold, urging the court to halt a land swap between Resolution Copper and the U.S. Forest Service. Plus the latest business, Fronteras Desk, and metro Phoenix news.

Luis Manuel Tumialán is a Professor of Neurosurgery at the Barrow Neurological Institute specializing in minimally invasive spinal surgery. He graduated from Georgetown University School of Medicine, completed his internship at the Naval Medical Center in San Diego. Dr. Tumialán completed additional training in undersea medicine in Groton Connecticut and Navy Dive School in Panama City, Florida. Upon completion of his operational training, he served as the Diving Medical Officer assigned to Naval Special Warfare Unit One in Guam during the Global War on Terror in the aftermath of September 11th, 2001. He received a Naval and Marine Corps Commendation Medal for service in support of Operation Enduring Freedom in Southeast Asia and a Navy Humanitarian Medal for the search and maritime rescue of a foreign national.Once he returned to the mainland, Dr. Tumialán completed his neurosurgery training at Emory University School of Medicine and returned to the Naval Medical Center in San Diego. He joined Barrow Brain and Spine in 2010 where he serves as the director of minimally invasive spine surgery. Dr. Tumialán's main interests are in minimally invasive spinal surgery and motion preservation surgery as well as developing techniques for the next generation of spinal surgery.

In this episode of Native Circles, Eva Bighorse and Dr. Farina King talk with Dr. Yvette Brown-Shirley, a Diné neurologist specializing in sports neurology and brain injury medicine at Barrow Neurological Institute. Dr. Brown-Shirley shares her experiences of becoming a neurologist and how her identity as a Diné woman healer informs her approach to medicine. She discusses the urgent need to address health inequities affecting Native communities, such as the lack of access to neurological care for Native American student-athletes facing risks of brain injuries. With a deep commitment to community engagement, she offers insights on fostering well-being and advocating for better recognition of brain health disparities.Additional Resources:Yvette Brown-Shirley, MD, Barrow Neurological Institute"Here Before, Hear Now Podcast: Dr. Yvette Brown-Shirley," Arizona's Family (3TV/CBS 5), March 18, 2024Boderra Joe, "Elevating neurological care: Diné female sports neurologist bringing light to brain health," Navajo Times, January 25, 2024.

In a conversation with CancerNetwork®, Shewetal Mehta, PhD, spoke about her research team's focuses in moving novel brain cancer therapies down the pipeline as part of an early phase clinical trials program at the Ivy Brain Tumor Center. Mehta, the deputy director and pre-clinical core leader at the Ivy Brain Tumor Center of Barrow Neurological Institute in Phoenix, Arizona, underscored a scientifically rigorous, patient-driven philosophy that drives her team members to deliver timely answers to those with brain cancer via work in a clinical lab and a pre-clinical arm. This collaboration helps identify therapeutic agents that may demonstrate activity in the brain while determining patient populations who are suitable to enroll on clinical trials. As part of her institution's early phase trial program, Mehta specifically highlighted work associated with a phase 0/1 clinical trial (NCT06072586) evaluating BDTX-1535, a brain-penetrant fourth-generation EGFR inhibitor, for those with recurrent high-grade glioma harboring oncogenic EGFR alterations or fusions.1 Investigators are incorporating liquid biopsy, sampling cerebrospinal fluid from patients on treatment to monitor potential evolutions or changes in brain tumors. Regarding biomarker testing, Mehta described the roles that gene sequencing and immunohistochemistry can play in identifying targetable alterations in patients with brain cancer. She mentioned vorasidenib (Voranigo), which received approval from the FDA in August 2024, as an example of a targeted therapy that may be suitable for use in patients who are found to have actionable IDH mutations. “Over the last year, we've seen that we were capable of not just doing these early phase clinical trials [but of entering] this phase of moving drugs into phase 3 [studies]. That's exciting,” Mehta stated regarding her outlook on the current state of brain cancer treatment. “Right now, we are excited about these new classes of agents that are within the space, like the proteolysis targeting chimeras, protein degraders, and antibody-drug conjugates, which have shown amazing promise in the rest of the oncology space.” References 1.        Study of BDTX-1535 in recurrent high-grade glioma (HGG) participants with EGFR alterations or fusions. ClinicalTrials.gov. Updated January 15, 2025. Accessed January 15, 2025. https://tinyurl.com/m6kwr2b3 2.        FDA approves vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. News release. FDA. August 6, 2024. Accessed January 20, 2025. https://tinyurl.com/25r9fkvy

We are kicking off the new year and a new season with a great guest! Dr. Kristen Steenerson, MD brings her expertise to the conversation with a deeper dive into Vestibular Migraine and Persistent Postural Perceptual Dizziness. Whether you're a patient or a clinician, you surely don't want to skip this episode! Kristen K. Steenerson, MD is a board-certified neurologist with fellowship training in vestibular neurology. She graduated cum laude from Claremont McKenna College, received her MD from the University of Utah, completed neurology residency at Mayo Clinic Arizona, and fellowship at Barrow Neurological Institute. She directs the Vestibular Balance Disorders Program of the Stanford Balance Center. She has joint appointments in the departments of Otolaryngology--Head and Neck Surgery and Neurology & Neurological Sciences at Stanford. Her clinical interests include vestibular migraine, persistent postural-perceptual dizziness, benign paroxysmal positional vertigo, Ménière's disease, and international neurology. Episode Resources - Central and peripheral vestibular disorders overview (and how much they overlap!): https://www.nature.com/articles/nrneurol.2017.58 - CGRP position paper: https://pubmed.ncbi.nlm.nih.gov/38466028/ - VMPATHI survey:https://redcap.ucsf.edu/surveys/?s=CY893NJHCM - VMPATHI paper: https://pubmed.ncbi.nlm.nih.gov/32176141/ - Comprehensive analysis of VM treatments: https://pubmed.ncbi.nlm.nih.gov/35859353/ - Migraine influences tinnitus and hearing loss: https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/ohn.201?casa_token=pfzZz62NjqcAAAAA:u0enZoqzF6n8D1_o_7G4HyTY5qpjFd0cDutwNpFtigKXd7xo4Zo65Cuzy4qZWjHDeuMICp0RYuKrGQ - Cognitive failures improve when migraine improves: https://pubmed.ncbi.nlm.nih.gov/37525385/ - Treat MdDS as migraine: https://pmc.ncbi.nlm.nih.gov/articles/PMC5823515/ - Magazine article: https://www.bustle.com/p/what-actually-happens-in-your-brain-when-you-have-a-migraine-according-to-experts-16823975 Hosted by Dr. Abbie Ross, PT, NCS, and Dr. Danielle Tolman, PT For Episode Recommendations or Requests, email us info@balancingactrehab.com Where to find us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://link.me/balancingactrehab⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.BalancingActRehab.com⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠Facebook: @BalancingActRehab Instagram: @BalancingActRehab Twitter: @DizzyDoctors TikTok: @BalancingActRehab

On Episode 47 of the Stroke Alert Podcast, host Dr. Negar Asdaghi is joined by Dr. Ashutosh Jadhav, Professor of Neurology and Neurosurgery at the Barrow Neurological Institute, for the 2024 Ralph Sacco Review of Top Cerebrovascular Research. In honor of the late Dr. Ralph L. Sacco, former Editor-in-Chief of Stroke, who died in January 2023, Drs. Asdaghi and Jadhav review some of the top cerebrovascular science published in any journal or presented at any scientific forum throughout the past year. For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20241213.415139

How is technology shaping the future of neurosurgery? In this episode, Bill sits down with Dr. Lawton, President and CEO of Barrow Neurological Institute, Robert F. Spetzler Endowed Chair for Neurosciences, and Chair of the Department of Neurosurgery. Dr. Lawton discusses the ways he is bringing new technologies and innovation to neurosurgery, as well as how it could improve patients outcomes and broaden the field's scope of impact.---------Key Quotes:“If we're able to have these huge datasets where we can take all the brain tumor patients and then go back 10 years before they were ever diagnosed and see what was abnormal then, it might open up these ways to predict or diagnose or even prevent some of these diseases before they get started.” “It's a technological revolution that has all of a sudden allowed us to envision things in neurosurgery that incorporate this tech in ways that we never had 20 years ago… I think probably the best example of that is the brain computer interface. There's the perfect example  of how technology and engineering brought into neurosurgery is going to change the world.”“Instead of taking just six variables, we can take a hundred variables and we can feed them into the black box of AI, and we can look at way more than just those six. And maybe our decision making will be better. Maybe our predictive powers will be different.”--------Timestamps: (02:26) Integrating technology in neurosurgery(06:37) Brain-Computer Interfaces (09:56) Expanding neurosurgical training(19:09) AI in neurosurgery: Diagnostics and beyond(29:16) Mysteries of the Mind and understanding the mind(34:35) Future of neurosurgery in emotional and cognitive interventions--------Sponsor:Edge solutions are unlocking data-driven insights for leading organizations. With Dell Technologies, you can capitalize on your edge by leveraging the broadest portfolio of purpose-built edge hardware, software and services. Leverage AI where you need it; simplify your edge; and protect your edge to generate competitive advantage within your industry. Capitalize on your edge today with Dell Technologies.--------Credits:Over the Edge is hosted by Bill Pfeifer, and was created by Matt Trifiro and Ian Faison. Executive producers are Matt Trifiro, Ian Faison, Jon Libbey and Kyle Rusca. The show producer is Erin Stenhouse. The audio engineer is Brian Thomas. Additional production support from Elisabeth Plutko.--------Links:Watch Dr. Lawton share his vision for how AI and edge solutions can be used to transform neurosurgeryFollow Dr. Lawton on X and InstagramLearn more about Barrow Neurological Institute and neurosurgeryGet to know Barrow President and CEO Michael T. Lawton, MDDiscover more about Barrow Neurological Institute's newest research quest to solve the mysteries of the mindWatch Dr. Lawton operate in this collection of neurosurgical operative videosFind out what it's like to be a neurosurgeon by watching three seasons of Barrow Neurosurgery Base CampFollow Barrow Neurological Institute on YouTube, Instagram, LinkedIn, X and FacebookFollow Bill on LinkedIn

In a conversation with CancerNetwork®, Yoshie Umemura, MD, offered various perspectives on progressing in the brain cancer treatment field. In addition to detailing institution-level advances in delivering multidisciplinary care, she highlighted her personal growth as she advanced in the neuro-oncology field while giving key advice to aspiring researchers who are in the early stages of their careers. Umemura, the chief medical officer of the Ivy Brain Tumor Center, division chief of Neuro-Oncology, and the William and Joan Shapiro chair of Neuro-Oncology at Barrow Neurological Institute, first described what drew her to studying neurology and eventually specializing in neuro-oncology, emphasizing the potential to form close connections with patients during treatment. Additionally, her collaborative approach to care and her institution's emphasis on multidisciplinary practice have helped in yielding various accomplishments, which included expediting the development of an investigator-initiated trial during the COVID-19 pandemic. The conversation also focused on the personal aspects of Umemura's neuro-oncology career. Delving into her experiences with immigrating to the United States when she was a high school student, she recalled feeling like an outsider as she learned to speak English and began to study neurology. However, she noted how several role models and mentors in the field have offered her guidance, which helped her grow and take on more leadership positions over time. Continuing to build upon the theme of collaboration in brain cancer research, Umemura emphasized the necessity of finding mentors even outside of one's institution to advance in the field. Additionally, as part of paying it forward to a new generation of neuro-oncologists, researchers should also become open to guiding others once they have gained enough experience.  “When you are at a conference and you meet someone you think you might click with, you're intrigued about, or you're impressed with, you can shoot an email and ask them if they would be open to chatting with you about a question or mentoring you,” Umemura said. “[You should also] pay it forward. Always be open to mentoring others; I think that's the only way to move forward….It [speaks] to the collaborative aspect and how to operate as an outsider. You're not an outsider as long as you make the connection; you can just wedge yourself in.”

In a conversation with CancerNetwork®, Nader Sanai, MD discussed the current state of the glioblastoma field, highlighting ongoing research efforts to help improve outcomes among patients with this disease.  Sanai is the director of the Ivy Brain Tumor Center and J.N Harber Professor of Neurological Surgery, Francis and Dionne Najafi chair for Neurosurgical Oncology, and chief of neurological oncology at Barrow Neurological Institute. Specifically, Sanai described plans to assess treatment with niraparib (Zejula) compared with temozolomide (Temodar) in a population of patients with newly diagnosed MGMT unmethylated glioblastoma as part of the phase 3 Gliofocus study (NCT06388733).1 He contextualized the rationale for conducting this study by focusing on findings from a proof-of-concept hybrid study (NCT05076513) and detailing how they supported additional investigation into the utility of niraparib.  According to findings from this proof-of-concept study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the median overall survival (OS) was 20.3 months among patients who received niraparib in combination with radiotherapy.2 Additionally, data showed that niraparib reached drug concentrations in Gadolinium-nonenhancing newly diagnosed glioblastoma tissue exceeding those of any other evaluated PARP inhibitors; investigators identified no new safety signals after combining niraparib with radiotherapy in this population. With the Gliofocus trial, Sanai and co-investigators aim to provide a clinically meaningful quality of life benefit with niraparib-based therapy beyond a marginally valuable statistical advantage. By evaluating treatment with niraparib, investigators look to improve historical survival rates reported with standard-of-care options among patients with unmethylated disease. “What we're looking to do with this trial is set a benchmark that's clinically relevant for patients and providers. The [OS] target for the study is 18 months, which is to effectively convert [a] 12-month natural history to a natural history closer to the methylated glioblastoma population,” Sanai said. “We think that is a meaningful transformation of a difficult patient population, a significant chunk of survival time that would be beneficial to patients, providers, and caregivers. Importantly, [it may also mean] an advantage for quality of life, which is of paramount importance for this patient population.” References 1.        A study comparing niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma. ClinicalTrials.gov. Updated June 24, 2024. Accessed September 16, 2024. https://tinyurl.com/y25er8p9 2.        Sanai N, Umemura Y, Margaryan T, et al. Niraparib efficacy in patients with newly-diagnosed glioblastoma: Clinical readout of a phase 0/2 "trigger" trial. J Clin Oncol. 2024;42(suppl 16):2002. doi:10.1200/JCO.2024.42.16_suppl.2002

Join us on 'Brain Tumor Talk' as we delve into the most commonly asked questions about radiation oncology, a key element of comprehensive cancer treatment, alongside surgery and chemotherapy. In this episode, Dr. William Kennedy, a distinguished radiation oncologist at the Ivy Brain Tumor Center at Barrow Neurological Institute, explores the role of radiation therapy in managing brain tumors.Dr. Kennedy explains the science behind radiation's ability to destroy tumor DNA. He highlights how advanced precision technology targets and eliminates cancer cells and discusses the creation of personalized radiation plans that balance maximum tumor control while preserving vital brain functions. These insights make this episode essential for patients, caregivers, and those interested in the latest developments in cancer radiation therapy.Learn more: https://www.ivybraintumorcenter.org/Follow Ivy Brain Tumor Center on Social: Instagram | Facebook | Twitter | LinkedInSign up for our monthly newsletter to stay informed about the latest in brain tumor research, treatment and community events.Request a No-Cost Clinical Trial Screening: https://www.ivybraintumorcenter.org/brain-tumor-clinical-trials/trialeligibility/ The information shared on this podcast is for educational and informational purposes only and serves as a starting point for you to have a conversation with your personal healthcare provider. Nothing stated on this podcast should be considered medical advice. You should always consult your personal physician or healthcare provider regarding your specific health concerns before beginning or changing any treatment plan. The views, opinions, and positions expressed by the host and guests on this podcast are theirs alone and do not necessarily reflect the views, opinions or positions of th...

The third in our brain aneurysm awareness month series does not disappoint! Gia Patel a teenage survivor of a brain aneurysm rupture comes on to talk about her experience and how she transformed it into an educational campaign supporting accurate diagnosis of childhood aneurysms. She also gives advice on storytelling, highlighting its importance for your recovery. Make sure to give this episode a listen and watch her documentary at Beyond a Headache Documentary.SummaryGia Patel, a brain aneurysm survivor, shares her story of experiencing a brain aneurysm rupture at the age of 14. Initially misdiagnosed as a migraine, Gia's symptoms included a thunderclap headache, neck numbness, sensitivity to light and sound, and vomiting. After multiple hospital visits and tests, including a CT scan and lumbar puncture, the brain bleed was finally confirmed. Gia underwent coiling surgery, but 30% of the aneurysm remained. She then had clipping surgery at Barrow Neurological Institute in Phoenix, Arizona, which successfully resolved the issue. Gia also discusses the memory loss and cognitive issues she experienced after the surgery, as well as ongoing headaches and the challenges of finding effective medications. Gia Patel shares her experience with brain aneurysm and the challenges she faced as a teenager. She discusses the difficulties of managing medications and balancing a social life while dealing with the effects of her condition. Gia also talks about the naming of her dog Ellie and the coincidental connection to Ellie's Law, a law advocating for brain aneurysm research funding. She highlights the importance of storytelling and community in raising awareness and supporting survivors. Gia also mentions her documentary, Beyond a Headache, which aims to educate and spread awareness about brain aneurysms.Keywordsbrain aneurysm, rupture, misdiagnosis, migraine, thunderclap headache, sensitivity to light and sound, vomiting, CT scan, lumbar puncture, coiling surgery, clipping surgery, memory loss, cognitive issues, headaches, medications, brain aneurysm, teenager, medications, social life, Ellie's Law, storytelling, community, documentary, Beyond a HeadacheTakeaways· Brain aneurysm ruptures can be misdiagnosed as migraines, so it's important to advocate for further testing if symptoms persist.· Symptoms of a brain aneurysm rupture can include a thunderclap headache, neck numbness, sensitivity to light and sound, and vomiting.· Treatment options for brain aneurysms include coiling and clipping surgeries, but the choice depends on the size and location of the aneurysm.· After brain surgery and aneurysm ruptures, patients may experience memory loss, cognitive issues, and ongoing headaches.· Finding effective medications for post-surgery symptoms can be challenging and may require experimentation.· Managing medications and balancing a social life can be challenging for teenagers with brain aneurysms.· Storytelling is a powerful tool for raising awareness and connecting with others who have similar experiences.· Community support is crucial for brain aneurysm survivors to feel validated and understood.· Gia Patel's documentary, Beyond a Headache, educates and spreads awareness about brain aneurysms.· Early detection and treatment of brain aneurysms can prevent life-threatening complications.Sound Bites"I...

Could long Covid cause other long-term cognitive issues? Barrow Neurological Institute's Dr. Marwan Sabbagh joins us to explain the results of a new study. 

In this month's Community Spotlight, Dr. Gonzalez with Barrow Neurological Institute joins us to talk about the warning signs of a stroke and how to tell if someone is experiencing one. 

Join us for the first episode of "Brain Tumor Talk" where we delve into the complexities of brain tumors with Dr. Nader Sanai, Director of the Ivy Brain Tumor Center and Chief of Neurosurgical Oncology at Barrow Neurological Institute. With over 1,300 brain tumor surgeries conducted annually, Barrow is one of the most active brain tumor treatment facilities in the U.S.In this episode, Dr. Sanai breaks down the basics of brain tumors, discussing their diverse types and the symptoms they can present. He explores why brain tumors are among the most complex and treatment-resistant cancers, highlighting the unique challenges they pose in finding effective treatments.You'll also learn about the latest advancements in brain tumor therapy, the critical role of clinical trials, and the ongoing efforts to develop new, more effective, and less toxic treatment options. Dr. Sanai shares his personal motivation for pursuing a career in neurosurgery and his persistent hope in the face of daunting challenges.Tune in to gain valuable insights into brain tumor care, understand the importance of drug development in oncology, and hear Dr. Sanai's inspiring vision for the future of brain tumor treatment. This episode is a must-listen for patients, caregivers, and anyone interested in the forefront of cancer research.Learn more: https://www.ivybraintumorcenter.org/Follow Ivy Brain Tumor Center on Social: Instagram | Facebook | Twitter | LinkedInSign up for our monthly newsletter to stay informed about the latest in brain tumor research, treatment and community events.Request a No-Cost Clinical Trial Screening: https://www.ivybraintumorcenter.org/brain-tumor-clinical-trials/trialeligibility/ The information shared on this podcast is for educational and informational purposes only and serves as a starting point for you to have a conversation with your personal healthcare provider. Nothing stated on this podcast should be considered medical advice. You should always consult your personal physician or healthcare provider regarding your specific health concerns before beginning or changing any treatment plan. The views, opinions, and positions expressed by the host and guests on this podcast are theirs alone and do not necessarily reflect the views, opinions or positions of th...

After months of secrecy, Neuralink revealed that the partner site for its brain implant study is the Barrow Neurological Institute. Read this story here. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr Charlie Teo is an Australian Neurosurgeon and the founder and director of the Charlie Teo foundation. Charlie has trained at distinguished centres such as the Barrow Neurological Institute, Johns Hopkins University, Duke University, Stanford University, Vanderbilt University and Harvard University. Charlie has been published in over 120 peer reviewed journals, has authored two books on keyhole approaches to brain tumours and featured as a guest editor for several journals. He was the Australian representative on the Tumour Section of the American Association of Neurological Surgeons (AANS) and CNS. In this interview today, Charlie & I discuss: - Charlie's Background - Why was Charlie cancelled? - What it's like having lives in your hands - Charlie's surgery success rate - Do no harm vs necessary risk-taking - How many patients has Charlie told that he wouldn't operate on? - The skill involved in brain injury - Why not retire? - Curing Brain Cancer - What would Charlie do if he had brain cancer? - Connect with Charlie Links: Charlie Teo foundation: https://charlieteofoundation.org.au Charlie's website: https://charlieteo.com.au Connect with us: https://freedompact.co.uk/newsletter​ (Healthy, Wealthy & Wise Newsletter) YouTube.com/ freedompact​ instagram.com/freedompact https://tiktok.com/personaldevelopment twitter.com/freedompactpod freedompact@gmail.com

Welcome back to the Neurophilia Podcast! In today's episode, we are joined by neuro-interventionalist and Stroke: Vascular and Interventional Neurology Editor in Chief, Dr. Ashutosh Jadhav to discuss interventional neurology. Throughout the hour we discussed the different paths to and collaborations within interventional neurology, celebrated the latest developments in the field, and highlighted the areas of growth in terms of increasing exposure to interventional neurology within neurology residency and around the globe. Dr. Ashutosh Jadhav is a vascular and interventional neurologist at the Barrow Neurological Institute in Phoenix, AZ. Dr. Jadhav attended Harvard University and graduated magna cum laude with a degree in biochemical sciences. He received his medical degree as well as a Doctoral in Philosophy (Genetics) from Harvard Medical School. He completed his residency and fellowship at Harvard Medical School and University of Pittsburgh. He serves as the editor-in-chief of Stroke: Vascular and Interventional Neurology.Follow Dr.  Ashutosh Jadhav on Twitter @AshuPJadhav Follow Dr.  Nupur Goel on Twitter @mdgoelsFollow Dr.  Blake Buletko on Twitter @blakebuletkoFollow the Neurophilia Podcast on Twitter and Instagram @NeurophiliaPodReferences:Asif, K. S., Otite, F. O., Desai, S. M., Herial, N., Inoa, V., Al-Mufti, F., Jadhav, A. P., Dmytriw, A. A., Castonguay, A., Khandelwal, P., Potter-Vig, J., Szeder, V., Kulman, T., Urrutia, V., Masoud, H., Toth, G., Limaye, K., Aroor, S., Brinjikji, W., … vu, T. thanh. (2023). Mechanical thrombectomy global access for stroke (MT-Glass): A mission thrombectomy (MT-2020 Plus) study. Circulation, 147(16), 1208–1220. https://doi.org/10.1161/circulationaha.122.063366 Limaye, K., Ortega-Gutierrez, S., Mokin, M., Jagolino, A., Sheth, S. A., & Jadhav, A. P. (2021). Exposure to neurointervention during neurology training. Stroke, 52(9). https://doi.org/10.1161/strokeaha.121.036026 Support the show

During tough moments, sometimes the best thing you can do is hold space.Dr. Charuta Furey has spent her entire career doing just that. As a trailblazing resident neurosurgeon at the Barrow Neurological Institute in Phoenix, Arizona, she leads patients and families through their darkest times with empathy and understanding. Throughout this discussion, she shares how she follows her clinical intuition, which has helped her navigate the challenges of balancing a demanding career with motherhood. In this episode, you'll discover the following:Dr. Furey's personal story of what drew her to neurosurgery and how her mother's battle with brain cancer shaped her career.The significance of empathy in patient care and how Dr. Furey navigates tough conversations with patients and their families.Strategies for balancing a demanding career with family life, including Dr. Furey's tips on being present and mindful in both roles.Dr. Furey's advice for patients recovering from surgery, particularly the importance of pre-surgery preparation.How cultivating gratitude and self-compassion helps Dr Furey remain grounded.Timestamps:0:00 - 1:26: Introduction1:28 - 9:08:  Journey to Neurosurgery and Empathy9:09 - 13:15: Navigating Tough Conversations13:16 - 17:43: Navigating the Demands of Career and Motherhood  17:53 - 21:04: Pre-surgery Preparation21:05 - 24:35: Handling Neurosurgery Challenges25:40 - 34:49: Navigating Patient Care and Patient Empowerment36:23 - 40:47: Support Systems40:48 - 41:57: Describing Work to Children42:08 - 43:59: Navigating Patient Recovery44:41 - 43:24: Cultivating Gratitude and Self-Compassion43:29 - 45:55: Conclusion Connect with Dr Charuta Furey:X: charutafureyLearn more about the Ivy Brain Tumor Center at Barrow Neurological Institute:Visit website: https://www.barrowneuro.org/Please make sure to subscribe so you don't miss an episode, and kindly review the podcast on Apple Podcasts so we can reach more working moms. We always want to hear your thoughts, concerns, questions or guest suggestions – email workingmomhour@212comm.com. Follow us! LinkedIn: https://www.linkedin.com/company/workingmomhour Instagram: https://www.instagram.com/workingmomhour/ TikTok: https:/www.tiktok.com/@workingmomhour Working Mom Hour Website: https://workingmomhour.com/ Subscribe to our YouTube channel: https://www.youtube.com/@workingmomhour

The key to understanding Alzheimer's disease could be in our genes. While the cause of Alzheimer's is still unknown, mounting research shows that carrying multiple copies of certain genes — like genetic variant ApoE4 — can significantly increase the likelihood of developing Alzheimer's. By studying genetics and gene therapy, scientists are learning more about how genes play a role in Alzheimer's disease and what can be done for prevention. Barrow Neurological Institute's neurologist, author, and Alzheimer's expert Dr. Marwan Sabbagh joins Being Patient to discuss how scientists are seeking to prevent Alzheimer's through genetic research. Sabbagh, a board-certified behavioral neurologist at Barrow's Alzheimer's and Memory Disorders Program and a professor at the institute's department of neurology, has served as the lead investigator on several prominent national Alzheimer's prevention and treatment clinical trials. In this talk, he'll speak about how genetic research, like that on the ApoE4 gene, can help us learn more about Alzheimer's and how it can be prevented. This Live Talk is sponsored by Alzheon.

The key to understanding Alzheimer's disease could be in our genes. While the cause of Alzheimer's is still unknown, mounting research shows that carrying multiple copies of certain genes — like genetic variant ApoE4 — can significantly increase the likelihood of developing Alzheimer's. By studying genetics and gene therapy, scientists are learning more about how genes play a role in Alzheimer's disease and what can be done for prevention. Barrow Neurological Institute's neurologist, author, and Alzheimer's expert Dr. Marwan Sabbagh joins Being Patient to discuss how scientists are seeking to prevent Alzheimer's through genetic research. Sabbagh, a board-certified behavioral neurologist at Barrow's Alzheimer's and Memory Disorders Program and a professor at the institute's department of neurology, has served as the lead investigator on several prominent national Alzheimer's prevention and treatment clinical trials. In this talk, he'll speak about how genetic research, like that on the ApoE4 gene, can help us learn more about Alzheimer's and how it can be prevented. This Live Talk is sponsored by Alzheon. Watch now to learn more about the genetics of Alzheimer's disease. If you loved watching this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/ Follow Being Patient: Twitter:   / being_patient_   Instagram:   / beingpatientvoices   Facebook:   / beingpatientalzheimers   LinkedIn:   / being-patient   Being Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia.

atching and accurately identifying a neurodegenerative disease like Alzheimer's or another form of dementia early can make all the difference in the world to a patient and their loved ones: An early diagnosis means more time to plan for the future, join a clinical trial testing cutting-edge disease-modifying treatments, making lifestyle changes to slow symptoms, or spending more time with loved ones. On the other hand, a misdiagnosis could mean that patients receive the wrong medications, causing harm — and unfortunately misdiagnoses are all too common when it comes to dementia. Why is this the case, and what can patients do about it? Neurologist, author, and Alzheimer's expert Dr. Marwan Sabbagh joins Being Patient Live Talks to discuss why dementias are so difficult to diagnose. Sabbagh, a board-certified behavioral neurologist at Barrow Neurological Institute's Alzheimer's and Memory Disorders Program and a professor at the institute's Department of Neurology, has served as the lead investigator on a number of prominent national Alzheimer's prevention and treatment clinical trials. In this talk, he'll speak to the factors that make dementia so difficult to diagnose accurately for experts and clinicians — as well as what patients and their families can do to advocate for an accurate diagnosis and a faster response to brain health concerns. Watch the full video to learn more about what caregivers and people living with dementia should know about diagnosis. If you loved watching this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/ Follow Being Patient: Twitter:   / being_patient_   Instagram:   / beingpatientvoices   Facebook:   / beingpatientalzheimers   LinkedIn:   / being-patient   Being Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://www.beingpatient.com/category...#Alzheimers #Dementia #BrainTalk #Diagnosis

Given that 30% of annual giving happens in December, it's crucial for nonprofits to have a winning year-end fundraising strategy. Calendar year-end fundraising leverages end-of-year tax benefits to motivate donors to give, while also aligning with the holiday spirit when people are more inclined to be charitable. In today's podcast episode, the IPM Advancement team shares their best tips for CYE fundraising, including the importance of major donors, why direct mail still matters, how to navigate 2023 trends and challenges, re-engaging lapsed donors, the role of self-care in fundraising, how to strategize for 2024, and more. Free 30-minute fundraising consultation for NPFX listeners: http://www.ipmadvancement.com/free Want to suggest a topic, guest, or nonprofit organization for an upcoming episode? Send an email with the subject "NPFX suggestion" to contact@ipmadvancement.com. Additional Resources [NPFX] Engaging Women Philanthropists to Improve Donor Retention https://www.ipmadvancement.com/blog/engaging-women-philanthropists-to-improve-donor-retention Best Wellness Practices for Nonprofit Fundraisers (#4 Might Surprise You) https://www.ipmadvancement.com/blog/best-wellness-practices-for-nonprofit-fundraisers-4-might-surprise-you [NPFX] Nonprofit Fundraising at Year-End: 4 Things to Do https://www.ipmadvancement.com/blog/nonprofit-fundraising-at-year-end-4-things-to-do IPM's free Nonprofit Resource Library: https://www.ipmadvancement.com/resources Michele Rebeor is a founder of Synergy Philanthropy and an IPM Advancement consultant. Her work supporting nonprofit organizations focuses on building and maximizing donor relationships that result in greater levels of giving. Michele also has a rare expertise in effecting strategies that acknowledge the role and importance of women donors and their impact on the future of philanthropy. https://www.linkedin.com/in/michelerebeor/ Samantha Timlick is the VP of Client Services at IPM Advancement. Since 2007 she has managed renewal, appeal, and acquisition programs encompassing more than 200 million total recipients — focusing on highly segmented direct mail microtargeting, personalized inbound and outbound telemarketing, and integrated e-campaigns. https://www.linkedin.com/in/stimlick/ Alan Knobloch is a founder of Synergy Philanthropy and an IPM Advancement consultant. He has worked in the nonprofit sector for over 30 years, holding positions at The Nature Conservancy Arizona, St. Joseph's Hospital and Barrow Neurological Institute, Phoenix Children's Hospital Foundation, and Valley of the Sun United Way. https://www.linkedin.com/in/alan-knobloch-8603347/ Melissa Cowley Wolf is the founder of MCW Projects and an IPM Advancement consultant. Melissa has more than 20 years of experience in philanthropy, specializing in next era philanthropic strategy, and organizational and executive wellness for leaders and collectives who want to make an impact. https://www.linkedin.com/in/melissa-cowley-wolf-6440a79/ Gina Parziale is a Certified Fundraising Executive and IPM Advancement consultant. With 20 years of experience in leadership and development for patients advocacy and nonprofit health organizations, Gina provides strategic planning, fundraising planning and execution, Board and staff development, therapeutic advancement, and engagement with industry to patient advocacy groups. https://www.linkedin.com/in/ginaparziale/ Russ Phaneuf, a co-founder of IPM Advancement, has a background in higher education development, with positions at the University of Hartford, Northern Arizona University, and Thunderbird School of Global Management. As IPM's managing director & chief strategist, Russ serves as lead fundraising strategist, award-winning content creator, and program analyst specializing in applied system dynamics. https://www.linkedin.com/in/russphaneuf/ Rich Frazier has worked in the nonprofit sector for over 30 years. In his role as senior consultant with IPM Advancement, Rich offers extensive understanding and knowledge in major gifts program management, fund development, strategic planning, and board of directors development. https://www.linkedin.com/in/richfrazier/

Yoshie Umemura, MD, talks about clinical trials for Neuro-Oncology. Dr. Umemura is the Division Chief of Neuro-Oncology, the William R. and Joan R. Shapiro Chair in Neuro-Oncology Research, associate professor of neurology at Barrow Neurological Institute, and Chief Medical Officer at the Ivy Brain Tumor Center. She is board certified in neurology by the American Board of Psychiatry and Neurology, as well as neuro-oncology by the United Council for Neurologic Subspecialties. Dr. Umemura's expertise rests on the axis of brain tumors and cancers of the central nervous system, as well as the neurological complications from cancer. She is a member of the American Academy of Neurology, the American Society of Clinical Oncology, the International Primary CNS Lymphoma Collaborative Group, and the Society for Neuro-Oncology. Dr. Umemura earned her medical degree from St. George's University School of Medicine in Grenada. She completed her neurology residency at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire and her neuro-oncology fellowship at Memorial Sloan Kettering Cancer Center in New York City.

Save Souls with an OfGod Tshirt: https://sjwellfire.com/shop/ Join our newsletter: https://sjwellfire.com/ Gab: https://gab.com/sjwellfire Support us to save souls via the news: https://sjwellfire.com/support/ or scott@sjwellfire.com paypal Prepare: https://sjwellfire.com/partners/ Whistleblower Reveals Military Mind Control Project At Major University What if the government could change people's moral beliefs or stop political dissent through remote control of people's brains? Sounds like science fiction, right? Well, a leaked document reveals that the US government, through DARPA research, is very close to accomplishing this. Activist Post was recently contacted by an anonymous whistleblower who worked on a secret ongoing mind-control project for DARPA. The aim of the program is to remotely disrupt political dissent and extremism by employing "Transcranial Magnetic Stimulation" (TMS) in tandem with sophisticated propaganda based on this technology. TMS stimulates the temporal lobe of the brain with electromagnetic fields. Below are snippets from the research contract that call Christians Extremists. Christians are not doing false flags like the Boston Bombing covered by RT or hitting the pentagon with a missile or planting bombs in the building where the IT servers are that had the 2.3 missing trillion dollars. Christians are not running the drugs like Iran Contra Affair or Vietnam or Afghanistan. Please. I bind this evil mindcontrolism tech in the name of Jesus Christ. INNOVATIVE CLAIMS Humans are storytelling beings. There is no clearer evidence of this than the struggles of the United States government to convince world populations of its good intentions, and to dissuade key constituencies from the powerful narratives told by violent extremists. In short, it is widely recognized that the U.S. is "losing the battle of the narrative" and thus, consequentially, the "war of ideas". This project responds to Technical Areas 1 and 2, with the aim of revolutionizing the study of the neuropsychology of narrative and its effects on persuasion. It will generate the knowledge to effectively understand, model, and disrupt narratives—systems of stories sharing themes, forms, and archetypes—on a neurological level, and the capability to induce powerful narrative phenomena (such as transportation and narrative validity) with certainty. To achieve this goal we have assembled a transdisciplinary team from Arizona State University and the Barrow Neurological Institute. Members have expertise in neuropsychology, neuroimaging, narrative theory, persuasion and strategic communication, as well as religion and culture. The team will achieve four key innovations in research approach, theory, and practice. Integrate narrative theory, neuroimaging, and persuasive outcomes. Each of these areas has been studied independently, but no effort to date has tested responses of the brain to narrative, and correlated those to attitude and behavior change. Our design integrates these concepts in all three project phases, meaning that the neural underpinnings of narrative can be directly linked to practical strategic communication outcomes. Resolve conceptual problems in narrative and psychology of religion. Most narrative theory comes from humanities, which favors interpretive analysis of single narratives (or small sets thereof), and tends to discount generalizable, quantitative, empirical research. Further, studies of the psychology of religion have historically been based on a “measurement paradigm” that takes little account of narrative structure of religious messages This project tests key narrative theories from communication, literary studies, and psychology in a design that will explain relative effects. It also uses stimuli based on religious master narratives—so often appropriated by extremist groups—to understand the psychological effects of particular message features and to attend to the relationship between narrative and political violence in contested populations, a small subset of which may engage in extremist behavior or financially, ideologically, or politically support extremists. Produce significant innovations in the study of the neuropsychology of narrative. While some research exists on how particular brain regions respond to narrative, none has identified brain networks that are responsible for narrative comprehension. This is a key shortcoming because the activity of any particular region is affected in complex ways by activity in other regions. Existing research also relies on fMRI methods that achieve poor temporal resolution. This prevents full understanding of how various regions work together over time to comprehend a narrative. Only by taking a holistic, multi-modal neuroimaging approach can we fully understand how narrative affects the brain. 7 III.A. STATEMENT OF WORK Scope This project integrates narrative theory, psychology of religion, neuropsychology, neuroimaging, and transcranial magnetic stimulation to describe, explain, and test the response of a Narrative Comprehension Network to stimuli based in religious master narratives. The project builds on a core within-subjects experimental design in the first phase, adding between- subjects manipulations in Phase II to test hypotheses about the functions of the network identified in that phase. Phase III seeks to manipulate key accessible areas via Transcranial Magnetic Stimulation to provide strong inferences about the role those areas play in comprehension. Finally, this project will create a fundamental basis for understanding how to disrupt or enhance aspects of narrative structure, and/or brain functioning, to minimize or maximize persuasive effects on subject proclivity to engage in political violence. Need for This Research This project integrates insights from three mutually-informing theoretical terrains: (1) narrative networks in circulation in contemporary cultures, particularly those narratives that are appropriated by extremists to promote, support, and justify violence; (2) brain networks, the neural and cognitive pathways through which the brain processes narrative as measured by multi-modal brain imaging techniques; and, (3) meaning networks or the patterns of interpretation and influence—attitudinal, intentional and behavioral changes—that accrue when narrative neural networks are activated. We will focus on religious narratives partly because of the theoretical opportunities they provide and partly because of their power in catalyzing extremist behavior. Subjects In this program of research we are focusing on members of two religious communities, Christians and Muslims . The choice of Christian and Muslim participants affords us a number of theoretical and practical opportunities. They share a number of key similarities for the purpose of our research, including several similar master narratives (e.g. they share cosmology, are monotheistic, and both are Abrahamic religions). They also have several importantly different master narratives (e.g. the primacy of Mohammed's prophecy for Muslims, the divinity of Jesus for Christians). We can leverage these similarities and differences to design our stimuli. There are several advantages to choosing religious narratives. First, religion is ubiquitous; every culture has some form of religion, and most people in the world are religious. Even if they are not, religious narratives pervade cultures in ways that religious master narratives are familiar to people even if they are not personally religious (Cohen, 2009; Saroglou & Cohen, in press). Third, they are particularly evocative. Religious narratives are among a small set of kinds of narratives that can guide people's ultimate concerns (Emmons, 2003), making people willing to devote their lives to the charitable service of others, to kill or die in the service of religion. We will also measure several individual difference variables related to religious outlooks: intrinsic religiosity, extrinsic religiosity, quest, and fundamentalism.

Denial of Payment after Successful Prior Authorization: The Latest Commercial Payer Ruse featuring Luis Tumialan, MD, FAANSLuis Manuel Tumialán is a Professor of Neurosurgery at the Barrow Neurological Institute specializing in minimally invasive spinal surgery. He graduated from Georgetown University School of Medicine, completed his internship at the Naval Medical Center in San Diego. Dr. Tumialán completed additional training in undersea medicine in Groton Connecticut and Navy Dive School in Panama City, Florida. Upon completion of his operational training, he served as the Diving Medical Officer assigned to Naval Special Warfare Unit One in Guam during the Global War on Terror in the aftermath of September 11th, 2001. He received a Naval and Marine Corps Commendation Medal for service in support of Operation Enduring Freedom in Southeast Asia and a Navy Humanitarian Medal for the search and maritime rescue of a foreign national.Once he returned to the mainland, Dr. Tumialán completed his neurosurgery training at Emory University School of Medicine and returned to the Naval Medical Center in San Diego. He joined Barrow Brain and Spine in 2010 where he serves as the director of minimally invasive spine surgery. Dr. Tumialán's main interests are in minimally invasive spinal surgery and motion preservation surgery as well as developing techniques for the next generation of spinal surgery.Dr. Tumialán has served as the Scientific Program Chairman and Annual Meeting Chairman for the AANS/CNS Spine Section, and currently serves as Secretary for that organization. He has also served as the Scientific Program Chair for the Society of Minimally Invasive Spinal Surgeons (SMISS) and the International Society for the Advancement of Spinal Surgery (ISASS). His interest in socioeconomics has led him to the Council of State Neurosurgical Societies (CSNS) where he has served as Treasurer, Corresponding Secretary and is currently the Vice Chair of the Organization.Dr. Tumialán is on the editorial board for both the Journal of Neurosurgery: Spine and Associate Editor for Operative Neurosurgery. He has authored over 100 peer reviewed publications and over 20 book chapters on spinal surgery.In 2020, Dr. Tumialán published a single authored textbook entitled “Minimally Invasive Spine Surgery: A Primer”. He lives in Phoenix, Arizona with his wife Andrea, his three sons (Julian, Andreas and Lucian) and his daughter (Soledad). 

Many smaller nonprofits don't have the budget to hire experienced fundraisers. They either make do with existing staff or hire a consultant that advises but doesn't implement. In today's episode, we explore the benefits of fractional fundraising — hiring a seasoned fundraiser for a fraction of the work week — and why this strategy can be a game changer for small nonprofits. Free 30-minute fundraising consultation for NPFX listeners: http://www.ipmadvancement.com/free Want to suggest a topic, guest, or nonprofit organization for an upcoming episode? Send an email with the subject "NPFX suggestion" to contact@ipmadvancement.com. Additional Resources Fractional Fundraising Services for Your Nonprofit https://www.ipmadvancement.com/fractional-fundraising IPM's free Nonprofit Resource Library: https://www.ipmadvancement.com/resources Trica Oshant Hawkins has worked for non-profit conservation organizations for most of her professional career. She received her BS in Wildlife Ecology, served as Education Specialist for Hawk Mountain Sanctuary in Pennsylvania for several years, and then returned to her Sonoran Desert home to co-found the Environmental Education Exchange, a non-profit organization with the mission of increasing environmental literacy through collaborative environmental education programs. After completing a Master's Degree in Conservation Biology, she shifted her focus from education to conservation, and began working with the Arizona Wildlife Federation (AWF). As AWF's Conservation Programs Director, Trica manages several programs that get people outdoors and directly involved in conservation projects. Trica also contributes to the organization's communications, education, and (for a brief spell) development programs. https://www.linkedin.com/in/trica-oshant-hawkins-1b40aa4a/ https://azwildlife.org/ Alan Knobloch has held positions in the nonprofit sector at The Nature Conservancy Arizona, St. Joseph's Hospital and Barrow Neurological Institute, Phoenix Children's Hospital Foundation, and Valley of the Sun United Way. In addition to being a Certified Fund Raising Executive from the Association of Fund Raising Professionals, he has earned a diploma from the National Planned Giving Institute from the College of William and Mary. Alan is a member of IPM Advancement's consultant network and a co-founder of Synergy Philanthropy. https://www.linkedin.com/in/alan-knobloch-8603347/ https://synergyphilanthropy.com/ Russ Phaneuf, a co-founder of IPM Advancement, has a background in higher education development, with positions at the University of Hartford, Northern Arizona University, and Thunderbird School of Global Management. As IPM's managing director & chief strategist, Russ serves as lead fundraising strategist, award-winning content creator, and program analyst specializing in applied system dynamics. Rich Frazier has worked in the nonprofit sector for over 30 years. In his role as senior consultant with IPM Advancement, Rich offers extensive understanding and knowledge in major gifts program management, fund development, strategic planning, and board of directors development.

On this month's community spotlight the Barrow Neurological team joins Jim and Jayme to talk about stroke awareness month and how to spot warning signs of a stroke.   See omnystudio.com/listener for privacy information.

Every now and then (about four times in a thousand episodes), we-revisit a slightly-updated version of an old episode, which proved to be super-popular first time around. This is such an episode. Many of you newbies have never listened to it, some hard-core TYPers have relistened a bunch of times and many have listened once and (understandably) forgotten most of what was spoken about. Anyway, growing up, Dr. Charlie Teo wanted to be either a rubbish collector (because they're fit), a bouncer (because he was a martial artist) or a mechanic (because he was into motorbikes - and still is). He actually started an apprenticeship as a mechanic before he studied medicine. This was a fascinating and meandering chat exploring Charlie's strategy for avoiding jet lag, neuroplasticity, improving with age, people wanting him to fail, dealing with criticism and hate, mapping the brain, a brain-machine interface, contact sports, poo transplants (yep), why he became a vegan, his exercise regime, our mutual love of motorbikes, patient-centred care, hanging out with the Dalai Lama 1 on 1 (for 4 hours), the power of kindness and lots more. BIO: For over 30 years Dr. Charlie Teo AM has been instrumental in the development, dissemination and acceptance of the concept of keyhole minimally invasive techniques in neurosurgery. Dr. Teo runs a fellowship program that attracts applicants yearly and has trained many of the world's leading figures in neurosurgery. He has trained at distinguished centres such as the Barrow Neurological Institute, Johns Hopkins University, Duke University, Stanford University, Vanderbilt University and Harvard University. charlieteofoundation.org.auSee omnystudio.com/listener for privacy information.

Dr. Alexander Whiting is a neurosurgeon and director of epilepsy surgery for Allegheny Health Network's Neuroscience Institute. He specializes in state-of-the-art epilepsy treatments, including stereoelectroencephalography (SEEG), seizure focus resections, laser ablations, vagal nerve stimulation, and responsive neurostimulation. Additionally, he has clinical interests in complex spine and brain disorders, and offers a range of surgical options and interventions for these conditions. Dr. Whiting completed his residency at the Barrow Neurological Institute in Phoenix, Arizona. He completed his fellowship in epilepsy surgery at the Cleveland Clinic in Cleveland, Ohio, and was awarded the American Epilepsy Society's prestigious Young Investigator Award. Today we speak to Dr. Whiting about SEEG.

Eisai Co., Ltd. and Biogen Inc. announced on January 6th that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb, which has the brand name in the United States of LEQEMBITM, for the treatment of Alzheimer's disease.  The approval is based on Phase 2 data that demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain, a defining feature of Alzheimer's disease.  Newt's guest is Dr. Marwan Sabbagh, MD.  He is a behavioral neurologist in the Alzheimer's and Memory Disorders Program and a professor in the Department of Neurology at Barrow Neurological Institute and was one of the leading doctors of the study.See omnystudio.com/listener for privacy information.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Marwan Sabbagh, MD, FAAN, a behavioral neurologist at the Barrow Neurological Institute. He joined the show to discuss the clinical trial results for lecanemab that were presented at the Clinical Trials on Alzheimer's Disease meeting in San Francisco, the drug's overall efficacy profile, as well safety information and the rates of ARIA, and more. Lecanemab (Biogen/Eisai), is a humanized monoclonal antibody that eliminates toxic amyloid-ß protofibrils that is set to follow aducanumab as the next approved treatment for patients with early Alzheimer disease. The FDA is set to decide on the treatment's approval by January 6, 2023. In the phase 3 Clarity AD study (NCT01767311), one of the supporting trials for its new drug application, lecanemab showed a statistically significant 27% reduction in the primary end point of Clinical Dementia Rating-Sum of Boxes when compared with placebo over an 18-month treatment period (P = .00005). Investigators reported an ARIA-edema rate of 12.5% for those on lecanemab compared with 1.7% for those on placebo. Symptomatic ARIA-E occurred at a rate of 2.8% in the lecanemab group and 0.0% in the placebo group. Looking for more Alzheimer disease discussion? Check out the NeurologyLive® dementia/Alzheimer clinical focus page: neurologylive.com/clinical/dementia-alzheimer Episode Breakdown: 1:20 – Lecanemab's safety profile from Clarity AD 4:15 – Amyloid-related imaging abnormalities and lecanemab use 6:40 – The landscape of Alzheimer disease therapeutics 8:10 – Neurology News Minute 10:15 – What research has revealed about treatment approaches 13:00 – How clinical trials have evolved in dementia research 14:40 – The possibility of induction therapy in Alzheimer disease 16:30 – Looking ahead to the next steps in treatment development 18:00 – Progress toward treating Alzheimer disease earlier This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023! Nominate: neurologylive.com/Giants-of-MS The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Roche Gets FDA Clearance for CSF Beta-Amyloid and Phospho-Tau Alzheimer Disease Assays BrainStorm Submits Type A Meeting Request Regarding NurOwn ALS Treatment Seizure-Free Days and Duration Intervals Increased with Fenfluramine in Dravet Syndrome Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCE 1. Irizarry M, van Dyck C, Sabbagh M, Bateman R, Cohen S. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer disease. Presented at: CTAD Conference, November 29-Dec 2.

Cuando uno piensa en la enfermedad de Parkinson (EP), es fácil asociarla más con los síntomas motores, como la rigidez o el temblor; pero también existen síntomas no motores, como los cambios de estado de ánimo, la ansiedad o la depresión.   En este episodio, hablamos con la doctora Elsa Baena, neuropsicóloga clínica en el Barrow Neurological Institute, Centro de Excelencia de la Parkinson's Foundation, acerca de estos cambios cognitivos asociados con el Parkinson.   La doctora Baena explica la conexión entre el Parkinson y la cognición y cómo pueden prepararse las personas con Parkinson para estos cambios (no sólo las maneras farmacológicas, sino también las terapéuticas).   Asimismo aprenderemos acerca de los miembros del equipo de atención médica que pueden apoyar a una persona con Parkinson y a sus familiares con estos cambios cognitivos.

This episode features Dr. David Wang, Co-Director of the Neurovascular Division & Petznick Stroke Center at Barrow Neurological Institute; Dr. Robert Lemery, Cardiac Electrophysiologist at Arizona Heart Rhythm Center; & Dr. Vijay Swarup, Director of Cardiac Electrophysiology at Arizona Heart Rhythm Center & Director of Electrophysiology at St. Joseph's Hospital. Here, they discuss details surrounding their collaborative work with The Arizona Brain and Heart Symposium taking place October 21st & 22nd, 2022. Learn more at https://www.barrowneuro.org/patient-care/support-resources/education-seminars/the-arizona-brain-and-heart-symposium/

Growing up, Dr. Charlie Teo wanted to be either a rubbish collector (because they're fit), a bouncer (because he was a martial artist) or a mechanic (because he was into motorbikes - and still is). He actually started an apprenticeship as a mechanic before he studied medicine. This was a fascinating and meandering chat exploring Charlie's strategy for avoiding jet lag, neuroplasticity, improving with age, people wanting him to fail, dealing with criticism and hate, mapping the brain, a brain-machine interface, contact sports, poo transplants (yep), why he became a vegan, his exercise regime, our mutual love of motorbikes, patient-centred care, hanging out with the Dalai Lama 1 on 1 (for 4 hours), the power of kindness and lots more. BIO: For over 30 years Dr. Charlie Teo AM has been instrumental in the development, dissemination and acceptance of the concept of keyhole minimally invasive techniques in neurosurgery. Dr. Teo runs a fellowship program that attracts applicants yearly and has trained many of the world's leading figures in neurosurgery. He has trained at distinguished centres such as the Barrow Neurological Institute, Johns Hopkins University, Duke University, Stanford University, Vanderbilt University and Harvard University. charlieteofoundation.org.auSee omnystudio.com/listener for privacy information.

#digitaltransformation #healthcare Data science, machine learning, and artificial intelligence have the potential to transform healthcare in profound ways. In this episode of CXOTalk, we speak to Dr. Shez Partovi, Chief Medical, Innovation & Strategy Officer at Royal Philips to discuss how these technologies are already improving patient outcomes, diagnosing disease, and more.The conversation includes these topics:-- On Philips as a health tech company-- On the role of data in healthcare transformation-- On the need to rethink data analytics in transforming healthcare-- On data collection and data sources in health transformation-- On linking data science in healthcare to improved patient outcomes-- On creating incentives for data-sharing in healthcare-- On choosing the right problems to solve in data science-- On avoiding bias in data-centric healthcare-- On patient lock-in based on data silos in healthcare-- On whom should be responsible for bad data, algorithms, and patient outcomes-- On the future of data and AI in healthcareSubscribe to be notified about our LIVE shows: https://www.cxotalk.com/subscribeRead the full transcript for this episode: https://www.cxotalk.com/episode/how-can-data-science-ai-transform-healthcareShez leads Philip's global Innovation & Strategy organization, including the Chief Technology Office, Research, HealthSuite Platforms, the Chief Medical Office, Product Engineering, Experience Design, and Strategy. Innovation & Strategy, in collaboration with the operating businesses and the markets, is responsible for directing the company strategy to delight our customers and advance our growth and profitability ambitions.Shez joined Philips from Amazon Web Services (AWS), where he served as Worldwide Head of Business Development for Healthcare, Life Sciences and Medical Devices. Prior to joining AWS in 2018, Shez spent 20 years at Dignity Health, the fifth largest health system in the U.S. He started his career in 1998 as a neuroradiologist at the Barrow Neurological Institute and was in clinical practice until 2013. In addition to his medical training at McGill University in Montreal, he has post-graduate qualifications in computer science. He helped launch the Biomedical Informatics Department at Arizona State University and taught there as a clinical professor for three years.

An injury to the spinal cord can be hugely traumatic and life-changing in nature. And while inroads have been made in terms of the development of treatments, there's still a way to go. But what are the treatments currently in development and are outcomes getting any better than they were 20 years ago? Dr. Rory Murphy is a neurosurgeon in the Department of Neurosurgery at Barrow Neurological Institute, in Phoenix, Arizona - he joined Jonathan to discuss.

“Dementia is not an aging disease; however, it is the most common disease among the aging population.” Dr. Babak Nayeri, Clinical Associate Professor from the University of Arizona, from the Netflix Documentary, This is Dementia. Watch this interview on YouTube here https://youtu.be/-U-slBBIEIA On this episode you will learn: ✔ Who is Dr. John Denboer, what he built, and lost in his passion to help mitigate dementia. ✔ What Dr. Denboer learned raising funds for a high growth startup. ✔ What is the difference between Alzheimer's Disease and Dementia? ✔ What can we all do now to mitigate this debilitating disease. ✔ How a tattoo with personal and professional meaning motivates Dr. Denboer to keep moving forward with his work. Welcome back to The Neuroscience Meets Social and Emotional Learning Podcast, for EPISODE #221. For those who are new here, I'm Andrea Samadi, author, and educator, with a passion for learning, understanding difficult concepts, and breaking them down so that we can all use and apply the most current research to improve our productivity and results in our schools, sports environments, and workplaces. This month, we are breaking into a new season on the podcast, Season 8, where our focus will be on Brain Health and Learning with a look at How an Understanding of Our Brain Can Improve Learning in Ourselves (adults, teachers, workers) as well as our future generations of learners. If you've been following our podcast over the seasons, you will know that our content took the turn towards health and wellness around September 2020 with a BONUS EPISODE where we covered the Top 5 Brain Health and Alzheimer's Prevention Strategies[i] after watching Dr. David Perlmutter's Alzheimer's The Science of Prevention Documentary.[ii] We took a closer look at Daily Exercise, Sleep, Eating a Healthy Diet, Optimizing our Microbiome, and Intermittent Fasting) as strategies we can all use to improve our brain health with the goal of preventing one of the most devastating degenerative diseases that affects “more than 5 million Americans (that is closer to 6 million now after reading our next guest's book) and is the most common form of dementia, a term that describes a variety of diseases and conditions that develop when nerve cells in the brain die or no longer function normally.”[iii] This number has reached “over 80 million cases globally and is expected to double to be 150 million cases by 2050.”[iv] (Denboer). On today's episode #221, we will be speaking with Dr. John Denboer, a former clinical neuropsychologist who specializes in early stage preventative medicine - including cognitive, physical exercise and nutrition – with a goal of slowing down the natural decline in patients with dementia. At peak, his practice served in the range of 10,000 patients in the US supported by over 100 employees.  I listened to a recent podcast Dr. Denboer did with Graham Brown on the XL Podcast[v] and learned that while Dr. Denboer has a passion for disrupting Dementia (the umbrella for degenerative diseases likes Alzheimer's and Parkinson's) that there have been many ups and downs in his start up journey as a pioneer in this field of health and wellness, disrupting Dementia. In today's interview, I'll ask him about the lessons he's learned along the way, the importance of family, and to explain his mission to make a difference for dementia sufferers and their loved ones before the global numbers go from 55 million people living with Dementia to doubling these numbers in the next 20 years. ***Just to note that John Denboer is not a current licensed psychologist / neuropsychologist / doctor and cannot provide medical advice. While researching Dr. Denboer I did see some things online that made me wonder why he is not a current licensed psychologist, and if you know me, getting to the truth of something is important. Instead of sweeping what I saw under the rug, I will ask him directly to explain what happened, so we can cover his journey with all the facts uncovered. Let's meet Dr.John Denboer and learn what we can do to disrupt dementia, strengthen our brains, and apply some of the lessons he's learned in his journey. Welcome Dr. John Denboer.  Intro: I've got to ask you, because I did notice before you sent me the note to be sure we say that you are not a current licensed psychologist/neuropsychologist/doctor that something happened to your license. When I'm researching someone, I always say, “if it's online, I'm going to see it.” Instead of just ignoring what I saw, can I ask, what happened to your license? Intro B: Dr. Denboer, I listened to a recent podcast you did, before I read your book, This is Dementia, or watched your Netflix  This is Dementia Documentary that goes hand in hand with the book, and it was a heartbreaking episode. It hit the heart for me, as I've been working the past 25+ years to bring awareness to important strategies and skills in our educational system (hence the name of the podcast Neuroscience Meets Social and Emotional Learning) and to do this, we have relied on grant funding with our work in the schools. Some competitive grants were won, others were lost, but my dollar amounts were nowhere near your dollar amounts lost with your start up. Can we start with a quick overview of what you built, what happened, and what you learned raising funds for a high growth startup, the successes/failures? Q1: I just interviewed Hilary Decesare,[vi] who appeared on that TV show Secret Millionaire on her new book coming out Relaunch and she talked about all the people she's helped over the years to start over. We've all been there at some point of time. What are you focused on now, and what is your vision for the future? Q1B: I watched your Netflix Documentary This is Dementia last night, and I did lose an Uncle who was diagnosed with early onset Alzheimers at 58, and it was a devastating experience to watch his decline. For those who don't know what Dementia is, can you explain the difference (Dementia vs Alzheimer's?) Q2: Can we mitigate dementia? What can we do right now to prevent this disease from impacting our brains? Can you explain what science knows about the brain and Alzheimer's and how Alzheimer's Disease affects the brain (our ability to think, remember and make decisions)? I do like to make sure we include the science in a way that we can all understand and learn something new. Is it just those 2 proteins Beta-Amyloid and Tao[vii] that do the damage in our brain, or is there more to it? Q1C: I did get my husband and I a brain scan[viii] to look and see what our brains looked like after I heard from Dr. Daniel Amen say that Alzheimer's can show up in the brain years before onset, but we can't all get our brains scanned and we were lucky to get his VIP rate since I did a podcast on the results. What can you share with us about early stage dementia detection since we can't all get our brains scanned until the cost comes down. What can we all look for and what prevention tip can we all implement immediately to prevent cognitive decline? Q2: When I saw your tattoo in the documentary, to motivate you personally and professionally, I related, as I recently got a tattoo for the same reason, and I draw on it daily to motivate me (it's on my ankle). You can't see your tattoo on your back though. Why did you put it there? Final Thoughts For people to reach out to you, and learn more, is the best place JohnDenboer.com? Dr. John Denboer, I want to thank you for coming on the podcast today, and being so open to share your journey with all of those who tune into the podcast. There are many lessons to learn from your experience, as well as the importance of listening to your heart and moving forward no matter what obstacles come your way. You surely have faced more obstacles than most of us, and your story shows that being a pioneer in the health care industry does take a unique and dedicated individual. I wish you all the success with your mission, and raising awareness for how we can all mitigate and slow down this devastating disease. Andrea's Final Thoughts Wow, that was a heartbreaking interview. I knew it was going to be difficult during the research phase, but knew there would be many lessons for all of us to hear. Since our focus of Season 8 is on brain health as it relates to learning, I wanted to debrief this interview, and think about everything that stood out to me. Lessons Learned from Dr. Denboer's Story Never a Lender nor a Borrower Be. The first lesson made me think of something my Dad used to say all the time, and is easy for us to see in hindsight. He would always say “Never a lender, nor a borrower be” and I know how difficult it must have been for Dr. Denboer to share the story of where borrowing money took him drastically off course. If you have ever been in a pinch financially (we all have been at some point), borrowing money to help get you past your difficult time isn't usually the best solution. Even if it's from someone you know well, and trust (like your family) it still does cause tension. The best solution, is to find another way forward (either by earning it yourself) or change the direction until you have the resources you need. I know that Dr. Denbouer wanted to share the details of his journey so that others could see where he made turns that sent him off course with his goals, so those listening can learn from his mistakes. Find a New Way Forward. We all get stuck, but when we know what we are meant to do, we must look for a new way forward. To see someone with years of work invested in his passion, lose their way, made me think of all the people who might have lost their way somehow during the Pandemic. I watched companies merge, and people being displaced, not sure of where to go next. I'm sure those of you listening could tell me a million stories, of loss and disappointment and as difficult times in our world continues, stories like John's aren't going to disappear. What I loved about this interview, is that Dr. Denboer is not giving up, and I know he will find a new way forward. He acknowledged how difficult it was, but he is clear on his direction, that his tattoo of his grandmother reminds him of daily. If you watch the interview, Dr. Denboer's face lit up when he spoke about his grandmother, and what she represents to him. If you have something important to you, like Dr. Denboer, you too will find a new way forward, if you've been taken off track. Keep Learning: We know that our brain health is crucial for all of us to live up to our full capacity, and Dr. Denboer reminded us that good cardiovascular health will get us 60% of the way, but to keep learning and doing things that stretch our brain in the process. I hope that you found Dr. Denboer's story to be helpful. If you want to reach out to him, go to JohnDenboer.com and send him a message. Like all of us, we could all use as much positive energy and love directed towards us, and our goals. I'll close with a quote from Steve Jobs, reminding us that “What we're doing here will send a giant ripple through the universe.” See you in a few days. Dr. John Denboer is a former clinical neuropsychologist specializing in the assessment and detection of early-stage dementia. He received his internship training at VA Boston Healthcare System (Boston University School of Medicine/Harvard University) and received his postdoctoral training at Barrow Neurological Institute. He has published extensively in the area of Clinical Neuropsychology and has been an expert speaker at many local, national, and international conferences. He is the Founder, CEO, and Chief Medical Officer of SMART Brain Aging, Inc., a company designed to help prevent and intervene in mild cognitive impairment and early-stage dementia. In the last 3 years, he has become a world-renown speaker in early-stage dementia detection and treatment. This has culminated in a Netflix documentary entitled “This is Dementia?!”[ix] as well as this book. REFERENCES: [i]The Top 5 Brain Health and Alzheimer's Prevention Strategies (Daily Exercise, Sleep, Eating a Healthy Diet, Optimizing our Microbiome, and intermittent Fasting). https://andreasamadi.podbean.com/e/do-you-know-the-top-5-brain-health-and-alzheimers-prevention-strategies-with-andrea-samadi/ [ii] Dr. David Perlmutter's “Alzheimer's: The Science of Prevention” https://scienceofprevention.com/ [iii] 10 Early Alzheimer's Symptoms That You Should Know https://www.amenclinics.com/blog/10-early-alzheimers-symptoms-that-you-should-know/ [iv] Disrupting Dementia TEDxGrandCanyonUniversity John DenBoer April 10, 2017 https://www.youtube.com/watch?v=R0xooSv6FkY&t=13s [v] https://podcasts.apple.com/dz/podcast/xl26-dr-john-denboer-disrupting-dementia/id1471486300?i=1000560704608 [vi]Neuroscience Meets Social and Emotional Learning Podcast EPISODE #219 Secret Millionaire Hilary Decesare On Her New Book Relaunch. https://andreasamadi.podbean.com/e/secret-millionaire-hilary-decesare-on-her-new-book-coming-june-9th-relaunch-spark-your-heart-to-ignite-your-life/ [vii] What Happens to the Brain in Alzheimer's Disease https://www.nia.nih.gov/health/what-happens-brain-alzheimers-disease [viii] Neuroscience Meets Social and Emotional Learning Podcast EPISODE #84 PART 3 “How a SPECT Image Brain Scan Can Change My Life: Andrea's Results” https://andreasamadi.podbean.com/e/how-a-spect-scan-can-change-your-life-part-3-with-andrea-samadi/ [ix] This is Dementia Netflix Documentary https://www.forbes.com/sites/robinseatonjefferson/2019/04/09/this-is-dementia-documentary-premiers-thursday-on-netflix/?sh=5ea60a61320c  

After two years of putting projects on hold, many nonprofits have decided its time to move forward with capital campaigns again. In today's episode, we discuss best practices to engage donors, how to make sure you're ready to launch your capital campaign, mistakes you want to avoid, and how campaigns might look different in 2022. Free 30-minute consultation for NPFX listeners: http://www.ipmadvancement.com/free Want to suggest a topic, guest, or nonprofit organization for an upcoming episode? Send an email with the subject "NPFX suggestion" to contact@ipmadvancement.com. Additional Resources IPM's free Nonprofit Resource Library: https://www.ipmadvancement.com/resources [NPFX] Nonprofit Feasibility Studies https://www.ipmadvancement.com/blog/nonprofit-feasibility-studies [NPFX] Capital Campaigns during COVID-19: Pivot and Adapt https://www.ipmadvancement.com/blog/capital-campaigns-during-covid-19-pivot-and-adapt Jarrett Ransom, aka the Nonprofit Nerd, has worked exclusively with nonprofit organizations for nearly 20 years. Over her career, Jarrett has served on multiple capital campaign teams totaling more than $86 million. Jarrett serves as the co-host of the American Nonprofit Academy's weekly "The Nonprofit Show," which features nonprofit thought leaders and topics. Alan Knobloch has held positions in the nonprofit sector at The Nature Conservancy Arizona, St. Joseph's Hospital and Barrow Neurological Institute, Phoenix Children's Hospital Foundation, and Valley of the Sun United Way. In addition to being a Certified Fund Raising Executive from the Association of Fund Raising Professionals, he has earned a diploma from the National Planned Giving Institute from the College of William and Mary. Rich Frazier has worked in the nonprofit sector for over 30 years. In his role as senior consultant with IPM Advancement, Rich offers extensive understanding and knowledge in major gifts program management, fund development, strategic planning, and board of directors development. Russ Phaneuf, a co-founder of IPM Advancement, has a background in higher education development, with positions at the University of Hartford, Northern Arizona University, and Thunderbird School of Global Management. As IPM's managing director & chief strategist, Russ serves as lead fundraising strategist, award-winning content creator, and program analyst specializing in applied system dynamics. 

The KTAR News Community Spotlight is on Barrow Neurological Institute. We discuss how it's important to understand the risks and KTAR's Detour Dan joined us to talk about the warning signs of a stoke. See omnystudio.com/listener for privacy information.

For some, the journey to their MS diagnosis is relatively quick and straightforward. For others, it can be lengthy and convoluted, sometimes  taking years. Joining me to talk about some of the twists and turns that can pop up on the road to being diagnosed with MS is Dr. Michael Robers, a neurologist in the Multiple Sclerosis Program and an assistant professor in the Department of Neurology at Barrow Neurological Institute. We're also talking about a study that measured MS prevalence among Black, White, Hispanic, and Asian people. We'll share results of a survey that looked at cannabis use among Canadians living with MS. We're also sharing results of a survey that looked at where Americans living with MS get their information about cannabis. If you're an MS caregiver, healthcare professional, or researcher, we'll give you the details about an important survey that you can participate in. And we're even taking a moment for a special thank you! We have a lot to talk about! Are you ready for RealTalk MS??! A quick look at the numbers and a heartfelt thank you!   :22 A date that each person remembers 2:59 Study looks at MS prevalence among different racial and ethnic groups  4:36 Survey results show cannabis use among Canadians with MS    7:41 Where do you get your information?  10:07 Survey results show where Americans with MS get their information and guidance about cannabis  11:20 An important survey for MS caregivers, healthcare professionals, and researchers  14:37 Dr. Michael Robers discusses the journey to an MS diagnosis  17:03 Share this episode  31:20 Download the RealTalk MS app for your iOS or Android device   31:41 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/245 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance STUDY: Racial and Ethnic Disparities in Multiple Sclerosis Prevalence https://n.neurology.org/content/98/18/e1818 SURVEY: Medical Cannabis Used in Canadians with Multiple Sclerosis https://www.msard-journal.com/article/S2211-0348(22)00153-5/fulltext SURVEY: Sources of Cannabis Information and Medical Guidance for Neurologic Use: NARCOMS Survey of People Living with Multiple Sclerosis https://cp.neurology.org/content/12/2/102 iConquer MS Survey for MS Caregivers https://survey.alchemer.com/s3/6823942/Caregiver-Survey-MS-Caregivers iConquer MS Survey for Researchers and Healthcare Providers https://survey.alchemer.com/s3/6823815/Caregiver-research-survey-HCPs-and-researchers Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 245 Guests: Dr. Michael Robers Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

Laura Dyrda shares the latest news on the Spine and Orthopedic industry.

In this week's episode, both our storytellers share their experience with the autism spectrum. This episode is in honor of World Autism Awareness Day, April 2, which hopes to further people's understanding and acceptance of autistic people.Part 1: Neuroscientist B. Blair Braden is confused as to why her neighbour doesn't pick up on any of her social cues.Part 2: For her entire life Behavioral Neuroscientist Susan Rapley doesn't understand why she can't fit in.B. Blair Braden received her doctorate in Behavioral Neuroscience, Psychology from Arizona State University (ASU). She completed her Neuroimaging/Neuropsychologoy Post-Doctoral Fellowship at Barrow Neurological Institute, St. Joseph's Hospital in Phoenix. She is an Assistant Professor of Speech and Hearing Science and Director of the Autism and Brain Aging Laboratory at ASU. Susan has a PhD in Psychological Neuroscience, then applied it to community science education and engagement. Throw in a healthy interest in leadership for social change, mix over maternity leave, then pour into disability equity for the NZ public service. Susan is currently advising in the establishment of NZ's new Ministry of Disabled People. Storytelling turns out to be at the heart of it all. Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this week's episode, both our storytellers share their experience with the autism spectrum. This episode is in honor of World Autism Awareness Day, April 2, which hopes to further people's understanding and acceptance of autistic people. Part 1: Neuroscientist B. Blair Braden is confused as to why her neighbour doesn't pick up on any of her social cues. Part 2: For her entire life Behavioral Neuroscientist Susan Rapley doesn't understand why she can't fit in. B. Blair Braden received her doctorate in Behavioral Neuroscience, Psychology from Arizona State University (ASU). She completed her Neuroimaging/Neuropsychologoy Post-Doctoral Fellowship at Barrow Neurological Institute, St. Joseph's Hospital in Phoenix. She is an Assistant Professor of Speech and Hearing Science and Director of the Autism and Brain Aging Laboratory at ASU. Susan has a PhD in Psychological Neuroscience, then applied it to community science education and engagement. Throw in a healthy interest in leadership for social change, mix over maternity leave, then pour into disability equity for the NZ public service. Susan is currently advising in the establishment of NZ's new Ministry of Disabled People. Storytelling turns out to be at the heart of it all. Learn more about your ad choices. Visit podcastchoices.com/adchoices

A familiar guest rejoins us for the show! Marwan Sabbagh MD is currently a professor of Neurology at Barrow Neurological Institute and a leader in Alzheimer's disease diagnosis and treatment. Dr. Sabbagh and his bestselling co-author and heart disease survivor, Joe Piscatella reveals new hope for treating and preventing these heart, blood vessel, and brain diseases like Alzheimer's with their new book, Strong Heart, Sharp Mind. We discuss how, for the first time in his career, Dr Sabbagh is starting to see people with very early Alzheimer's hold the symptoms at bay. He attributes, in part, to the development of new medications for Alzheimer's (listen to podcast episode #64) as well as the adoption of principles of a healthy lifestyle and specific new blood tests such as homocysteine to assess the risk of heart and brain diseases. The new book outlines 6 Key Principles to improve your brain, blood vessel, and heart health 1) Incorporating exercise into daily activities Check out the broomstick kayaking idea (very clever) 2) Transforming the American diet into a healthful way to eat Think about habits not diets or "fad diets." Trusted info from: Nutrition Action, the Berkeley Wellness Letter the Tufts Newsletter "even modest adoption of the MIND diet approach, such as eating two vegetable servings a day, two berry servings a week, and one fish meal a week, appeared to lower the risk of Alzheimer's disease." 3) Building a healthy sleep regimen 4) Managing stress, anger, and anxiety great section on anger and your health 5) Creating opportunities for cognitive stimulation 6) Bolstering your social support system To learn more about your assessment options for prevention or treatment of cognitive issues or Alzheimer's contact Kemper Cognitive Wellness in Cleveland, Ohio. Email: info@kemperwellness.com Website: https://kemperwellness.com/ Phone: (216) 337-1400.

Nick Theodore is a Professor of Neurosurgery at The Johns Hopkins University. He is known for his work in spinal trauma, robotics, and personalized medicine. He is Director of the Neurosurgical Spine Program and Co-Director of the Carnegie Center for Surgical Innovation at Johns Hopkins. Dr. Theodore graduated from Cornell University, attended medical school at Georgetown University, and completed his neurosurgical residency and fellowship in spinal surgery at the Barrow Neurological Institute. After completing his training in 2001, Dr. Theodore served as Chief of the Division of Neurosurgery at Naval Medical Center San Diego, overseeing the largest neurosurgery complement in the Navy. In 2003, he joined the faculty at the Barrow Neurological Institute and assumed the position of Director of Neurotrauma. In 2009 he became the Chief of the Spine Section at the Barrow Neurological Institute and was appointed the Volker K.H. Sonntag Chair in 2015. In 2016 he became the second Donlin M. Long Professor of Neurosurgery & Orthopaeidcs at Johns Hopkins University. Dr. Theodore is also actively involved in the area of preventative medicine within neurosurgery. He has been associated with the ThinkFirst Foundation for several years actively having served as the foundation's Medical Director and President. In 2017, Dr. Theodore was appointed to the Head, Neck and Spine Committee of the NFL.